Shares of obesity drug developer Aardvark Therapeutics (NASDAQ:AARD) closed 11% lower following a $94M initial public offering. Read more here.

Clinical-stage biopharmaceutical company Aardvark Therapeutics (AARD) priced its IPO of ~5.89M shares at $16.00 per share. All of the shares are being offered by Aardvark. The California-based startup ...

Metsera, a clinical-stage biotechnology firm, debuted on the Nasdaq Global Select Market today. After initially offering its ...

SailPoint said on Tuesday it was targeting a valuation of up to $11.5 billion in its New York flotation, as the cybersecurity ...

SailPoint intends to use its net proceeds from this offering to repay a portion of its term loan, settle outstanding equity awards and equity appreciation rights, pay outstanding fees under the ...

But these launches have largely been met with tepid market reaction. The Nasdaq's president still thinks this year could be the IPO market's comeback year. "I do think we start seeing things really ...

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...

Beta Bionics (BBNX) leads innovation in the diabetes treatment market with its groundbreaking iLet Bionic Pancreas technology ...